DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

13 Drugs in Development

13 Drugs in Development

DIGITAL CONTENT

12 NEWS #PharmaBuzz

media
12 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

13DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1218942-37-0, Gkt137831, Setanaxib, Gkt-137831, Gkt-831, Gkt831

Molecular Formula

C₂₁H₁₉ClN₄O₂

Molecular Weight

394.9 g/mol

InChI Key

RGYQPQARIQKJKH-UHFFFAOYSA-N

FDA UNII

45II35329V

Setanaxib is an orally bioavailable inhibitor of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX) 1 and 4, with potential anti-inflammatory, anti-fibrotic and antineoplastic activities. Upon oral administration, setanaxib targets, binds to and inhibits the activity of NOX1 and NOX4. This inhibits NOX1- and NOX4- mediated signal transduction pathways, thereby reducing inflammation and fibrosis. By targeting NOX4-overexpressing cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME), setanaxib may also inhibit myofibroblastic activation and enhance both the penetration of tumor-infiltrating lymphocytes (TILs) and antitumor T-cell immune responses. The NOX enzymes NOX1 and NOX4 primarily produce reactive oxygen species (ROS), which plays important roles in cellular signaling processes that regulate cell proliferation, differentiation and migration, and inflammation and fibrosis.

1 2D Structure

Setanaxib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6-dione

2.1.2 InChI

InChI=1S/C21H19ClN4O2/c1-24(2)14-8-6-7-13(11-14)20-19-16(12-18(27)25(20)3)23-26(21(19)28)17-10-5-4-9-15(17)22/h4-12,23H,1-3H3

2.1.3 InChI Key

RGYQPQARIQKJKH-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CN1C(=O)C=C2C(=C1C3=CC(=CC=C3)N(C)C)C(=O)N(N2)C4=CC=CC=C4Cl

2.2 Other Identifiers

2.2.1 UNII

45II35329V

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1h-pyrazolo(4,3-c)pyridine-3,6(2h,5h)-dione

2. Gkt-137831

3. Gkt-831

4. Gkt137831

5. Setanaxib

2.3.2 Depositor-Supplied Synonyms

1. 1218942-37-0

2. Gkt137831

3. Setanaxib

4. Gkt-137831

5. Gkt-831

6. Gkt831

7. 2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1h-pyrazolo(4,3-c)pyridine-3,6(2h,5h)-dione

8. 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione

9. 45ii35329v

10. 2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1,2-dihydro-3h-pyrazolo[4,3-c]pyridine-3,6(5h)-dione

11. Unii-45ii35329v

12. 1h-pyrazolo(4,3-c)pyridine-3,6(2h,5h)-dione, 2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-

13. 1h-pyrazolo[4,3-c]pyridine-3,6(2h,5h)-dione, 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-

14. Gkt 137831

15. Setanaxib [inn]

16. Gtpl9932

17. Schembl1302603

18. Chembl4303187

19. Dtxsid30153432

20. Ex-a577

21. Bcp14159

22. Mfcd27923122

23. S7171

24. Zinc95670835

25. Akos022176138

26. Ccg-268595

27. Cs-3290

28. Sb19230

29. Ncgc00378460-05

30. Ncgc00378460-08

31. Ncgc00378460-09

32. Ac-33132

33. As-74753

34. Da-33605

35. Hy-12298

36. Ft-0700121

37. A14433

38. J-690070

39. Q27258840

40. 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h,2h,3h,5h,6h-pyrazolo[4,3-c]pyridine-3,6-dione

41. 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methylpyrazolo[4,3-c]pyridine-3,6(2h,5h)-dione

2.4 Create Date

2012-08-19

3 Chemical and Physical Properties

Molecular Formula	C₂₁H₁₉ClN₄O₂
Molecular Weight	394.9 g/mol
XLogP3	3.2
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	3
Exact Mass	394.1196536 g/mol
Monoisotopic Mass	394.1196536 g/mol
Topological Polar Surface Area	55.9 Å²
Heavy Atom Count	28
Formal Charge	0
Complexity	732
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1